Prot# 6002-US-013: A 12-Wk, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy & Safety of a 20mg/d Oral Dose of KW-6002(Istradefylline)as Treatment for Parkinson's Disease in Patients w/Mo

Project: Research project

Project Details

StatusFinished
Effective start/end date8/11/04 → 3/5/07

Funding

  • PharmaNet, Inc. (6002-US-013 // 6002-US-013)
  • Kyowa Hakko Kirin Pharma, Inc. (6002-US-013 // 6002-US-013)